BeOne Medicines

ONC · Nasdaq · Switzerland

Share price · ONC

$403.60+34.45 (+9.33%) 3M

close as of 2026-11-18 · 24h delayed · vol 243K (0.6x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when ONC's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 4 Nov 2026+6.4%
  2. 15 Oct 2026+6.4%
  3. 6 Jul 2026+4.0%
  4. 28 May 2026-3.1%
  5. 26 Feb 2026-8.5%
  6. 25 Feb 2026-4.5%
  7. 28 Jan 2026+4.1%
  8. 13 Jan 2026+5.1%
  9. 9 Jan 2026+5.5%

Share of unusual movement by asset

For each asset, the share of ONC's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Daraxonrasib (Rasonque)
events and moves
257%
Tislelizumab
events and moves
156%
zanubrutinib (Brukinsa)
events and moves
134%
Zanidatamab
events and moves
234%
Sonrotoclax (Beqalzi)
events and moves
7shown from 8 days
BGB-B2033
events and moves
1shown from 8 days
BAT1706 (Avzivi)
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—3%
Other company news (earnings, financing, releases naming no asset)—17%
Sessions with no dated event—59%

Assets

(10 total)
10Total Assets
6Approved
2Phase 3 / Filed
2Phase 1–2 / Early
18Diseases
Quick filter:
Showing 10 of 10 assets
Target & Modality
BAT1706(Avzivi)
Approved
VEGF-AMonoclonal antibody
Non-Small Cell Lung CancerOvarian CancerCervical CancerColorectal CancerRenal Cell CarcinomaGlioblastoma
Daraxonrasib(Rasonque)
Approved
pan-RAS · RAS (pan-RAS, RAS-mutant tumors)Small molecule
Non-Small Cell Lung CancerPancreatic Ductal Adenocarcinoma
Sonrotoclax(Beqalzi)
Approved
BCL-2Small molecule
Acute Myeloid LeukemiaMantle Cell LymphomaChronic Lymphocytic Leukemia
Approved
PD-1Monoclonal antibody
Non-Small Cell Lung CancerSmall Cell Lung CancerGastric CancerNasopharyngeal CarcinomaEsophageal Cancer
Esophageal Squamous Cell Carcinoma
Approved
HER2Multispecific antibody
Non-Small Cell Lung CancerBiliary Tract CancerBreast CancerGastric Cancer
HER2-Positive Breast Cancer
zanubrutinib(Brukinsa)
Approved
BTKSmall molecule
Follicular LymphomaMantle Cell LymphomaChronic Lymphocytic Leukemia
Phase 3
CDK4Small molecule
Breast Cancer
HR+/HER2- Metastatic Breast Cancer
Phase 3
GPC3 (glypican-3) x 4-1BB (CD137)Multispecific antibody
Non-Small Cell Lung CancerHepatocellular Carcinoma
Phase 1
CDK2Small molecule
Breast Cancer
HR+/HER2- Metastatic Breast Cancer
Phase 1
BCL-2Small molecule
Breast Cancer
HR+/HER2- Metastatic Breast Cancer

Upcoming events

(33 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (4)
November 2026 (2)
Sonrotoclax · BeqalziPhase 1/2Relapsed/Refractory Multiple Myeloma
Est. primary completion 2026-11 · NCT04973605 · CT.gov ↗
What to watch
Sonrotoclax · BeqalziPhase 2Chronic Lymphocytic Leukemia
Est. primary completion 2026-11 · NCT06637501 · CT.gov ↗
What to watch
December 2026 (2)
ZanidatamabPhase 2Breast Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Cancer, Colorectal Cancer, Endometrial Cancer …
Est. primary completion 2026-12-31 · NCT06695845 · CT.gov ↗
What to watch
Tislelizumab + zanubrutinib · BrukinsaPhase 3B-cell Malignancies
Est. primary completion 2026-12-31 · NCT04170283 · CT.gov ↗
What to watch
2027 (7)
March 2027 (1)
Tislelizumab + BGB-B2033Phase 1/2Metastatic Hepatocellular Carcinoma, Local Advanced Hepatocellular Carcinoma, Alpha-fetoprotein (AFP)-Producing Gastric Cancer …
Est. primary completion 2027-03-31 · NCT06427941 · CT.gov ↗
What to watch
May 2027 (1)
Daraxonrasib · RasonquePhase 1/2Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors
Est. primary completion 2027-05-31 · NCT05379985 · CT.gov ↗
What to watch
June 2027 (1)
Daraxonrasib · RasonquePhase 1/2Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer, Lung Cancer Stage IV …
Est. primary completion 2027-06 · NCT06162221 · CT.gov ↗
What to watch
October 2027 (2)
zanubrutinib · BrukinsaPhase 2/3Primary Membranous Nephropathy
Est. primary completion 2027-10 · NCT05707377 · CT.gov ↗
What to watch
TislelizumabPhase 3Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
Est. primary completion 2027-10-30 · NCT07043400 · CT.gov ↗
What to watch
December 2027 (2)
Daraxonrasib · RasonquePhase 3NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma) …
Est. primary completion 2027-12-01 · NCT06881784 · CT.gov ↗
What to watch
ZanidatamabPhase 2HER2-positive Breast Cancer, Breast Cancer
Est. primary completion 2027-12-29 · NCT07102381 · CT.gov ↗
What to watch
2028 (11)
February 2028 (1)
TislelizumabPhase 2Advanced Esophageal Squamous Cell Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma
Est. primary completion 2028-02-28 · NCT07733180 · CT.gov ↗
What to watch
March 2028 (1)
BGB-B2033Phase 2Hepatocellular Cancer, Liver Cancer, Hepatocellular Carcinoma
Est. primary completion 2028-03-31 · NCT07911683 · CT.gov ↗
What to watch
April 2028 (2)
Daraxonrasib · RasonquePhase 3Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC) …
Est. primary completion 2028-04 · NCT07491445 · CT.gov ↗
What to watch
ZanidatamabPhase 3Metastatic HER2-positive Breast Cancer
Est. primary completion 2028-04-28 · NCT06435429 · CT.gov ↗
What to watch
July 2028 (1)
zanubrutinib · BrukinsaPhase 3Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma
Est. primary completion 2028-07 · NCT05100862 · CT.gov ↗
What to watch
August 2028 (2)
Sonrotoclax · BeqalziPhase 1/2Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm
Est. primary completion 2028-08-31 · NCT04771130 · CT.gov ↗
What to watch
Sonrotoclax · BeqalziPhase 3Mantle Cell Lymphoma, B Cell Lymphoma
Est. primary completion 2028-08-31 · NCT06742996 · CT.gov ↗
What to watch
September 2028 (1)
Daraxonrasib · RasonquePhase 1/2Colorectal Cancer, CRC, Pancreatic Ductal Adenocarcinoma, PDAC, Gastrointestinal Cancer, Metastatic Pancreatic Ductal Adenocarcinoma
Est. primary completion 2028-09-30 · NCT06445062 · CT.gov ↗
What to watch
December 2028 (3)
Daraxonrasib · RasonquePhase 1/2Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
Est. primary completion 2028-12 · NCT06128551 · CT.gov ↗
What to watch
ZanidatamabPhase 3Biliary Tract Cancer
Est. primary completion 2028-12-01 · NCT06282575 · CT.gov ↗
What to watch
Sonrotoclax · Beqalzi + zanubrutinib · BrukinsaPhase 1/2B-cell Malignancy, Relapsed Cancer, Refractory Cancer, B-cell Lymphoma
Est. primary completion 2028-12-02 · NCT06634589 · CT.gov ↗
What to watch
2029 (7)
March 2029 (1)
Daraxonrasib · RasonquePhase 3Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC) …
Est. primary completion 2029-03 · NCT07805954 · CT.gov ↗
What to watch
April 2029 (1)
BGB-43395Phase 3HR+/HER2- Breast Cancer
Est. primary completion 2029-04 · NCT07492641 · CT.gov ↗
What to watch
May 2029 (2)
Daraxonrasib · RasonquePhase 1/2Advanced Solid Tumors, Metastatic Solid Tumors, Non-small Cell Lung Cancer (NSCLC), NSCLC, Colorectal Cancer (CRC), CRC
Est. primary completion 2029-05 · NCT07397338 · CT.gov ↗
What to watch
Daraxonrasib · RasonquePhase 3Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma (PDAC) …
Est. primary completion 2029-05-10 · NCT07252232 · CT.gov ↗
What to watch
September 2029 (2)
BGB-B2033Phase 3Hepatocellular Carcinoma, Liver Cancer
Est. primary completion 2029-09-21 · NCT07836530 · CT.gov ↗
What to watch
Sonrotoclax · BeqalziPhase 3Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Est. primary completion 2029-09-30 · NCT06943872 · CT.gov ↗
What to watch
November 2029 (1)
Sonrotoclax · Beqalzi + zanubrutinib · BrukinsaPhase 1/2Chronic Lymphocytic Leukemia, CLL, Mantle Cell Lymphoma, MCL
Est. primary completion 2029-11-30 · NCT06697184 · CT.gov ↗
What to watch
2030 (1)
April 2030 (1)
Sonrotoclax · BeqalziPhase 1/2Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, B-cell Acute Lymphoblastic Leukemia, Pediatric Cancer, Pediatric ALL …
Est. primary completion 2030-04-30 · NCT07770698 · CT.gov ↗
What to watch
2031 (2)
February 2031 (1)
Sonrotoclax · Beqalzi + zanubrutinib · BrukinsaPhase 3Chronic Lymphocytic Leukemia
Est. primary completion 2031-02 · NCT07277231 · CT.gov ↗
What to watch
December 2031 (1)
TislelizumabPhase 2Advanced Unresectable Gastric Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Advanced Gastroesophageal Adenocarcinoma
Est. primary completion 2031-12-31 · NCT07554521 · CT.gov ↗
What to watch
2032 (1)
February 2032 (1)
Est. primary completion 2032-02 · NCT06073821 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(14)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

16 November 2026ApprovalDaraxonrasibEuropean Commission approves Rasonque in previously treated metastatic pancreatic adenocarcinoma
EU, European Commission · Source ↗
31 August 2026Topline resultZanidatamabPhase 3 HERIZON-GEA-01 second interim analysis: ZIIHERA plus chemotherapy improved overall survival versus trastuzumab plus chemotherapy
26 August 2026ApprovalDaraxonrasibFDA approves Rasonque (daraxonrasib) in metastatic pancreatic cancer
US, FDA · Source ↗
25 August 2026ApprovalZanidatamabFDA approves Ziihera regimens in first-line HER2+ gastroesophageal adenocarcinoma
US, FDA · Source ↗
25 August 2026ApprovalTislelizumabFDA approved the TEVIMBRA sBLA for first-line HER2+ gastroesophageal adenocarcinoma (with ZIIHERA and chemotherapy)
US, FDA · Source ↗
25 August 2026FDA action dateZanidatamabPDUFA target date August 25, 2026
US, FDA · Source ↗
August 2026ApprovalZanidatamabFDA updates Boxed Warning on Zanidatamab (BLA761416)
US, FDA · FDA · Source ↗
22 July 2026Filing acceptedDaraxonrasibFDA accepts the daraxonrasib NDA in previously treated metastatic pancreatic cancer
US, FDA · Revolution Medicines · Source ↗
June 2026Topline resultzanubrutinibZanubrutinib plus rituximab Phase 3 MANGROVE (NCT04002297) in untreated mantle cell lymphoma: positive topline results
BeOne Medicines Ltd. · Source ↗
27 April 2026Filing acceptedZanidatamabFDA accepts Ziihera sBLA for first-line HER2+ GEA
US, FDA · Source ↗
27 April 2026Priority reviewZanidatamabFDA grants Priority Review to Ziihera sBLA
US, FDA · Source ↗
29 August 2025Topline resultBGB-11417Phase 1/2 BGB-11417-201 (NCT05471843) of sonrotoclax in R/R MCL met its primary endpoint
BeOne Medicines · Source ↗

The 12 most recent of 14 past events are shown.

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$1.9B$661M$5.9B—$509M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$1.7B$612M$5.3B—$463M operating cash flowreport ↗
2026-Q1$1.5B—$4.8B—report ↗
2025-Q3$1.4B$524M$4.1B—$403M operating cash flowreport ↗
2025-Q2$1.3B$525M$2.8B—$264M operating cash flowreport ↗
2025-Q1$1.1B$482M$2.5B—$44M operating cash flowreport ↗
2024-Q3$1.0B$496M$2.7B$121M$188M operating cash flowreport ↗
2024-Q2$929M$454M$2.6B$120M-$96M operating cash flowreport ↗
2024-Q1$752M$461M$2.8B+ $0 short-term inv.$251M-$309M operating cash flowreport ↗
2023-Q3$781M$453M$3.1B+ $107M short-term inv.—-$78M operating cash flowreport ↗
2023-Q2$595M$423M$3.4B+ $106M short-term inv.$381M-$294M operating cash flowreport ↗
2023-Q1$448M$409M$3.5B+ $294M short-term inv.$348M-$564M operating cash flowreport ↗
2022-Q3$388M$426M$4.2B+ $872M short-term inv.$558M-$562M operating cash flowreport ↗
2022-Q2$342M$378M$4.5B+ $1.2B short-term inv.$571M-$380M operating cash flowreport ↗
2022-Q1$307M$390M$4.4B+ $1.9B short-term inv.$434M-$237M operating cash flowreport ↗
2021-Q3$206M$352M$1.4B+ $2.5B short-term inv.$414M-$496M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$5.3B$2.1B$4.6B—$1.1B operating cash flowreport ↗

BeOne Medicines reported full-year 2025 revenue of $5,343.03M, up 40.2% YoY, with R&D spend of $2,145.87M, up 9.9% YoY. Cash and equivalents stood at $4,609.65M at year-end, and the company reported full-year GAAP net income of $286.9M.

For full-year 2026, the company guided total revenue to $6.2 billion to $6.4 billion. Key developments included first global approvals for sonrotoclax in China in relapsed/refractory mantle cell lymphoma and CLL/SLL, FDA priority review for sonrotoclax in R/R MCL, long-term BRUKINSA data from the SEQUOIA and ALPINE trials presented at ASH, and positive HERIZON-GEA-01 survival results for TEVIMBRA in HER2-positive gastroesophageal adenocarcinoma.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$3.8B$2.0B$2.6B$161M-$141M operating cash flowreport ↗
2023-FY$2.5B$1.8B$3.2B+ $2.6M short-term inv.$220M-$1.2B operating cash flowreport ↗
2022-FY$1.4B$1.6B$3.9B+ $665M short-term inv.$501M-$1.5B operating cash flowreport ↗
2021-FY$1.2B$1.5B$4.4B+ $2.2B short-term inv.$353M-$1.3B operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 204 sales ($384.7M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-09Wang Xiaodong · directorGift1,183——Form 4
2026-11-06Ball Titus B. · Principal Accounting OfficerOption exercise880$207.55$183KForm 4
2026-11-06Ball Titus B. · Principal Accounting OfficerOption exercise679$159.03$108KForm 4
2026-11-06Ball Titus B. · Principal Accounting OfficerOpen-market sale1,533$405.55$622KForm 4
2026-11-06Ball Titus B. · Principal Accounting OfficerOpen-market sale26$406.34$11KForm 4
2026-11-06Ball Titus B. · Principal Accounting OfficerOption exercise (derivative)11,440——Form 4
2026-11-06Ball Titus B. · Principal Accounting OfficerOption exercise (derivative)8,827——Form 4
2026-11-05Lee Chan Henry · SVP, General CounselOpen-market sale660$400.00$264KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 279 reporting institutions held 34.8M shares ($10.2B, 31.3% of shares outstanding).

#InstitutionSharesValue
1BAKER BROS. ADVISORS LP8,799,053$2.6B
2PRIMECAP MANAGEMENT CO/CA/4,975,181$1.5B
3Capital International Investors4,158,726$1.2B
4FMR LLC3,693,610$1.1B
5Capital World Investors1,622,687$481.9M
6HHLR ADVISORS, LTD.1,034,306$307.2M
7CITADEL ADVISORS LLC1,032,298$306.6M
8Temasek Holdings (Private) Ltd862,643$256.2M
9BlackRock, Inc.657,501$195.3M
10Siren, L.L.C.465,000$138.1M
11MORGAN STANLEY464,472$137.9M
12UBS Group AG415,330$123.3M
13BANK OF AMERICA CORP /DE/405,273$120.4M
14Baird Financial Group, Inc.349,651$103.8M
15Capital International, Inc./CA/302,243$89.8M